Denosumab: a new treatment option for glucocorticoid-induced osteoporosis

Affiliations

¹ Department of Medicine III, and Center for Healthy Aging, Technische Universität Dresden Medical Center, Fetscherstraße 74, 01307 Dresden, Germany.
² Department of Medicine III, and Center for Healthy Aging, Technische Universität Dresden Medical Center, Fetscherstraße 74, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden, Dresden, Germany. Electronic address: lorenz.hofbauer@uniklinikum-dresden.de.

Comment

Elena Tsourdi et al. Lancet Diabetes Endocrinol. 2018 Jun.

. 2018 Jun;6(6):428-429.

doi: 10.1016/S2213-8587(18)30097-4. Epub 2018 Apr 6.

¹ Department of Medicine III, and Center for Healthy Aging, Technische Universität Dresden Medical Center, Fetscherstraße 74, 01307 Dresden, Germany.
² Department of Medicine III, and Center for Healthy Aging, Technische Universität Dresden Medical Center, Fetscherstraße 74, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden, Dresden, Germany. Electronic address: lorenz.hofbauer@uniklinikum-dresden.de.

No abstract available

Comment on

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF. Saag KG, et al. Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6. Lancet Diabetes Endocrinol. 2018. PMID: 29631782 Clinical Trial.